Affibody and Inmagene announce First Patient Dosed in the Global Phase 2 ASPIRE Trial of izokibep for patients with active Ankylosing Spondylitis
Partners will continue to file Investigational New Drug (IND) Applications in additional applications in autoimmune diseases during 2021. San Diego, U.S., Shanghai, China, and Solna, Sweden, August 25, 2021. Inmagene